Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 9/20 | 0.38 |
| ▸ | CA2 | P00918 | 9/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873813 | 1.00 | ADK (0.43) | ADKGSK3BTSHRCA1CA2 | |
| SCHEMBL6886938 | 0.86 | XDH (0.48) | ADKGSK3B | |
| SCHEMBL3691849 | 0.85 | ADORA1 (0.37) | ADKGSK3B | |
| SCHEMBL6305780 | 0.84 | CA5A (0.43) | — | |
| SCHEMBL29022774 | 0.78 | GDA (0.48) | GSK3B | |
| SCHEMBL28631534 | 0.78 | GDA (0.48) | GSK3B | |
| SCHEMBL28542110 | 0.78 | GDA (0.48) | GSK3B | |
| SCHEMBL5472025 | 0.77 | CDK1 (0.42) | ADK | |
| SCHEMBL5474432 | 0.77 | CDK1 (0.42) | ADK | |
| SCHEMBL31108455 | 0.77 | GDA (0.47) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107109458-B | Cell-based defibrotide potency assay | 真蒂奥姆责任有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-2107909-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX Pharmaceuticals, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008082602-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1439220-B1 | Immobilized biocatalysts usable for the manufacture of natural nucleosides and modified analogues through enzymatic transglycosylation reactions | ADORKEM TECHNOLOGY SPA (IT) | 2007-08-22 | — | — | EP | disclosed |
| US-20040142438-A1 | Novel immobilized biocatalysts usable for the production of natural nucleosides and modified analogues by enzymatic transglycosylation reactions | KERYOS SPA (IT) | 2004-07-22 | — | — | US | disclosed |
| EP-1439220-A1 | Immobilized biocatalysts usable for the manufacture of natural nucleosides and modified analogues through enzymatic transglycosylation reactions | Keryos Spa (IT) | 2004-07-21 | — | — | EP | disclosed |